Rapid, actionable intelligence in 2 hours
CHICAGO, March 27 /PRNewswire/ -- Celsis International plc , a global leader in rapid microbial detection solutions for industry, today announces the launch of Celsis ReACT(TM), the first easy-to-use RNA-based assay for detecting objectionable organisms quickly and definitively without the need for expensive equipment or specialized training.
Manufacturers of pharmaceutical, beauty and home care products using Celsis Rapid Detection systems for their primary screening of raw materials, in-process and finished goods can now utilize this new RNA-based assay to obtain a fast, 2-hour result on samples that test positive for microbial contamination. Celsis ReACT assays use proprietary selections of ribosomal RNA sequences to confirm or to rule out the presence of Gram-negative organisms, Staph. aureus, yeast and mold, and can be customized for facility-specific or wild strain organisms.
"Serious contamination events, while somewhat rare, do happen. When they occur they can cost companies hundreds of thousands, if not millions of dollars," explained Jay LeCoque, Celsis CEO. "We developed Celsis ReACT for our customers who have asked for a way to quickly and easily determine if they have an objectionable organism, so they can minimize the financial impact to their operations and bottom line."
The faster a company can confirm that a sample has been contaminated by an objectionable organism, the faster the contaminated batch can be stopped before it reaches the production line or, even worse, is released for sale. In addition, a faster reaction means fewer potentially contaminated additional batches will be produced, thus significantly reducing the financial impact of lost product and product disposal.
Celsis customers will be able to use Celsis ReACT following the primary Celsis AKuScreen(TM) assay, which definitively detects the presence or absence of microbial organisms in 18-24 hours instead of the typical 3-5 days for microbial limits testing. The same primary system has also been proven successful in equaling the traditional 14-day sterility test in less than half the time. Following a positive result on the Celsis primary system, the new Celsis ReACT assays use Celsis' existing instrument platform to provide rapid, actionable intelligence and secondary analysis within 2 hours.
"Celsis ReACT offers our customers the speed, simplicity and reliability of Celsis Rapid Detection systems combined with the precision of advanced molecular biology," said Lori Daane, Ph.D., a microbiologist and vice president of scientific affairs and customer service for Celsis Rapid Detection. The industry's easiest-to-use RNA system, Celsis ReACT uses simple protocols with user-friendly, color-coded steps. Basic measuring and pipetting skills are all that's required technically, and the Celsis system provides fast, clear results in two hours. With minimal training, existing customers can immediately adopt this new RNA-based testing system and begin to realize the benefits of fast, definitive results.
For more information about Celsis ReACT, visit www.celsis.com/react or contact Celsis Rapid Detection at +1 312 476 1282.
About Celsis Rapid Detection Systems
Celsis Rapid Detection systems provide significant economic value to manufacturers by significantly reducing the time required to test and release raw materials, in-process solutions and finished goods to market. Pharmaceutical and consumer products manufacturers using Celsis systems realize improved cash flow and reduce their inventory and working-capital requirements, while ensuring quality and increased responsiveness throughout the supply chain.
About Celsis International plc
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries. Each Celsis division delivers substantial time and cost savings to its customers while ensuring product quality and safety for consumers. Celsis' extensive client base includes many of the world's leading pharmaceutical and consumer products companies. The Company is listed on the London Stock Exchange (CEL.L).
CONTACT: Cindy Lieberman, Corporate Marketing of Celsis International plc,
+1-312-476-1200, Fax, +1-312-476-1201, email@example.com; or Andrea
Davis of Outlook Marketing Services, Inc., +1-312-873-3421,
firstname.lastname@example.org, for Celsis
Web site: http://www.celsis.com/